dc.contributor.author | Ustun, C | |
dc.contributor.author | Celebi, H | |
dc.contributor.author | Uysal, A | |
dc.contributor.author | Aydintug, S | |
dc.contributor.author | Demirer, S | |
dc.contributor.author | Akan, H | |
dc.contributor.author | Koc, H | |
dc.contributor.author | Demirer, T | |
dc.contributor.author | Ilhan, O | |
dc.contributor.author | Mandel, NM | |
dc.contributor.author | Arat, M | |
dc.contributor.author | Gunel, N | |
dc.date.accessioned | 2021-03-06T20:33:34Z | |
dc.date.available | 2021-03-06T20:33:34Z | |
dc.date.issued | 2000 | |
dc.identifier.citation | Demirer T., Ilhan O., Mandel N., Arat M., Gunel N., Celebi H., Ustun C., Akan H., Demirer S., Aydintug S., et al., "A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies", BONE MARROW TRANSPLANTATION, cilt.25, ss.697-703, 2000 | |
dc.identifier.issn | 0268-3369 | |
dc.identifier.other | av_facb2f65-041c-45d4-8479-55d303f5454c | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/164184 | |
dc.identifier.uri | https://doi.org/10.1038/sj.bmt.1702239 | |
dc.description.abstract | The purpose of this study was to determine the maximum tolerated dose of carboplatin administered with 500 mg/m(2) thiotepa and 100 mg/m(2) melphalan followed by autologous peripheral blood stem cell (PBSC) infusion in patients with refractory malignancies. Twenty-eight patients with refractory malignancies received high-dose thiotepa (500 mg/m(2), melphalan (100 mg/m(2)) and escalating doses of carboplatin 900-1500 mg/m(2)) followed by infusion of cryopreserved autologous PBSCs, The maximum tolerated doses were determined to be 500 mg/m(2) thiotepa, 100 mg/m(2) melphalan and 1350 mg/m(2) carboplatin. Two consecutive patients receiving 1500 mg/m(2) carboplatin experienced grade 3 mucositis and colitis, Ten patients were enrolled at the maximum tolerated dose and none had grade 3-4 regimen-related toxicity and mortality. All patients at this level experienced grade 1-2 mucositis, 90% grade 1-2 gastrointestinal toxicity, 30% grade 1-2 cardiac and renal toxicity, and 10% experienced grade 1 hepatic toxicity, The median time to achieve a granulocyte count of 0.5 x 10(9)/l was 9 days (range 7-12 days) and platelet count of 20 x 10(9)/l was 10 days (range 7-15 days), Of eight patients with stage IV refractory breast cancer, even were evaluable for response, one patient on day 75 will be evaluated soon. Five of seven (71.5%) evaluable patients achieved a complete remission (CR) and two had no response. Of seven patients with non-Hodgkin's lymphoma (n = 4) or Hodgkin's disease (n = 3), five achieved a CR (71.5%). Thiotepa, melphalan and carboplatin can be administered in high doses with tolerable mucositis as the major side-effect. This combination has significant activity in patients with breast cancer, and phase II studies in patients with breast cancer and other chemotherapy-sensitive malignancies are warranted. | |
dc.language.iso | eng | |
dc.subject | Onkoloji | |
dc.subject | BİYOFİZİK | |
dc.subject | Biyoloji ve Biyokimya | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.subject | ONKOLOJİ | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | HEMATOLOJİ | |
dc.subject | İmmünoloji | |
dc.subject | TRANSPLANTASYON | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Temel Tıp Bilimleri | |
dc.subject | Biyofizik | |
dc.subject | Biyokimya | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Hematoloji | |
dc.subject | İç Hastalıkları | |
dc.subject | Temel Bilimler | |
dc.subject | Yaşam Bilimleri | |
dc.title | A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies | |
dc.type | Makale | |
dc.relation.journal | BONE MARROW TRANSPLANTATION | |
dc.contributor.department | , , | |
dc.identifier.volume | 25 | |
dc.identifier.issue | 7 | |
dc.identifier.startpage | 697 | |
dc.identifier.endpage | 703 | |
dc.contributor.firstauthorID | 125489 | |